Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Combo Lipid-Lowering Drugs Will Help Drive Cholesterol Market In 2007 – IMS

Executive Summary

Patent losses this year for blockbuster lipid-lowering agents including Merck's Zocor (simvastatin) and Bristol-Myers Squibb's Pravachol (pravastatin) will cause a six percentage point drop in growth in the class in 2007, but the advent of combination therapies are expected to help offset the negative impact, IMS Health projects
Advertisement

Related Content

Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone
Invega Approval Gives J&J A Year To Move Risperdal Patients To Paliperidone
Bristol/Sanofi Push Plavix To Exhaust Generic Supply; Levels Remain Unclear
Rising Drug Use Stems From Changes In Clinical Guidelines – PhRMA Report
Rising Drug Use Stems From Changes In Clinical Guidelines – PhRMA Report
Plavix Generic Blocked By Court, But Damage Lingers For Bristol And Sanofi
Advertisement
UsernamePublicRestriction

Register

PS047746

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel